Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Bowen’s disease – a review of newer treatment options

Authors Thorsten Neubert, Percy Lehmann

Published 10 October 2008 Volume 2008:4(5) Pages 1085—1095

DOI https://doi.org/10.2147/TCRM.S1960

Thorsten Neubert, Percy Lehmann

Zentrum für Dermatologie, Allergologie und Umweltmedizin, Helios Klinikum Wuppertal, Klinikum der Universität Witten-Herdecke, Wuppertal, Germany

Abstract: Bowen’s disease (squamous cell carcinoma in situ) has a 3%–5% risk to develop into invasive squamous cell carcinoma. Non-melanoma skin cancer is the most common cancer among Caucasians and its incidence has increased during the last decades dramatically. Multiple treatment options for Bowen’s disease have been described and are established with advantages and disadvantages. Bowen’s disease occurs more often in elderly patients (with a higher risk of comorbidities) and is frequently located on body sites with poor wound healing. Therefore there is need for non-invasive/non-destructive but effective treatment options. We would like to give an overview of established therapies and more detailed information about the newer treatment options for Bowen’s disease with topical diclofenac, topical imiquimod and photodynamic therapy.

Keywords: Bowen’s disease, photodynamic therapy, imiquimod, diclofenac

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Evaluation of 188Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model

Huang FYJ, Lee TW, Chang CH, Chen LC, Hsu WH, Chang CW, Lo JM

International Journal of Nanomedicine 2015, 10:463-473

Published Date: 9 January 2015

High gene delivery efficiency of alkylated low-molecular-weight polyethylenimine through gemini surfactant-like effect

Liu S, Huang W, Jin MJ, Wang QM, Zhang GL, Wang XM, Shao S, Gao ZG

International Journal of Nanomedicine 2014, 9:3567-3581

Published Date: 28 July 2014

Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer

Thérèse H Franco, Ahmed Khan, Vishal Joshi, Beje Thomas

Therapeutics and Clinical Risk Management 2008, 4:1367-1370

Published Date: 5 December 2008

Beta-glucans in the treatment of diabetes and associated cardiovascular risks

Jiezhong Chen, Kenneth Raymond

Vascular Health and Risk Management 2008, 4:1265-1272

Published Date: 5 December 2008

Clinical studies with oral lipid based formulations of poorly soluble compounds

Dimitrios G Fatouros, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz

Therapeutics and Clinical Risk Management 2007, 3:591-604

Published Date: 15 September 2007

Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results

Marco Metra, Savina Nodari, Tania Bordonali, Patrizia Milani, Carlo Lombardi, et al

Therapeutics and Clinical Risk Management 2007, 3:569-578

Published Date: 15 September 2007

Recognition of transorbital intracranial injury ||FREE PAPER||

Roger E Turbin, Flora Levin, Dawn N Maxwell

Clinical Ophthalmology 2007, 1:85-89

Published Date: 15 June 2007